Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
Primary Purpose
Diabetes Mellitus, Type 2
Status
Terminated
Phase
Phase 1
Locations
Denmark
Study Type
Interventional
Intervention
Metformin
Caffeine
Efavirenz
Losartan
Omeprazol
Metoprolol
Midazolam
Sponsored by

About this trial
This is an interventional other trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes, not treated metformin.
- Hemoglobin 1Ac (HbA1c): ≥48 mmol/mol
- Age: 18-75 years
- Body Mass Index (BMI) ≤ 40 kg/m2
- Estimated Glomerular Filtration Rate (eGFR) > 60 mL/min
- Alanine Aminotransferase (ALAT), bilirubin and hemoglobin within reference range or clinically insignificant differ from this.
Exclusion Criteria:
- Acute or chronic infection or inflammation
- Active cancer
- Glutamic acid decarboxylase (GAD)-antibodies
- Known hypersensitivity to one or several of the drugs
- Intake of medications which can influence the safety of the patient or the results of the study
- Alcohol consumption above the limits recommended by the Danish Health Authorities (Men 14 units/week, women 7 units/week)
- Participation in other trials with interventions.
- Women: Positive pregnancy test at inclusion or on one of the test-days.
Sites / Locations
- University of Southern Denmark
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Metformin
Arm Description
Patients will receive metformin 1000-2000 mg daily for 12 weeks.
Outcomes
Primary Outcome Measures
Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 3.
Change in activity of the drug metabolizing enzyme CYP3A4 following treatment with the glucose lowering drug metformin in 3 weeks. Assessment of the change is based on a change in the metabolic rate, which is the ratio between the concentration of midazolam and its primary metabolite is plasma (Probe drug for CYP3A4).
Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 12.
Change in activity of the drug metabolizing enzyme CYP3A4 following treatment with the glucose lowering drug metformin in 12 weeks. Assessment of the change is based on a change in the metabolic rate, which is the ratio between the concentration of midazolam and its primary metabolite is plasma (Probe drug for CYP3A4).
Secondary Outcome Measures
Change from Baseline in Metabolic Rate of Caffeine (CYP1A2) at Week 3.
Change in activity of the drug metabolizing enzymes CYP1A2 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug caffeine.
Change from Baseline in Metabolic Rate of Caffeine (CYP1A2) at Week 12.
Change in activity of the drug metabolizing enzymes CYP1A2 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug caffeine.
Change from Baseline in Metabolic Rate of Efavirenz (CYP2B6) at Week 3.
Change in activity of the drug metabolizing enzymes CYP2B6 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Efavirenz.
Change from Baseline in Metabolic Rate of Efavirenz (CYP2B6) at Week 12.
Change in activity of the drug metabolizing enzymes CYP2B6 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Efavirenz.
Change from Baseline in Metabolic Rate of Losartan (CYP2C9) at Week 3.
Change in activity of the drug metabolizing enzymes CYP2C9 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Losartan.
Change from Baseline in Metabolic Rate of Losartan (CYP2C9) at Week 12.
Change in activity of the drug metabolizing enzymes CYP2C9 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Losartan.
Change from Baseline in Metabolic Rate of Omeprazole (CYP2C19) at Week 3.
Change in activity of the drug metabolizing enzymes CYP2C19 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Omeprazole.
Change from Baseline in Metabolic Rate of Omeprazole (CYP2C19) at Week 12.
Change in activity of the drug metabolizing enzymes CYP2C19 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Omeprazole.
Change from Baseline in Metabolic Rate of Metoprolol (CYP2D6) at Week 3.
Change in activity of the drug metabolizing enzymes CYP2D6 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Metoprolol.
Change from Baseline in Metabolic Rate of Metoprolol (CYP2D6) at Week 12.
Change in activity of the drug metabolizing enzymes CYP2D6 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Metoprolol.
Change from Baseline in HbA1c at Week 3.
Change in the regulation of blood glucose over time assessed by HbA1c
Change from Baseline in HbA1c at Week 12.
Change in the regulation of blood glucose over time assessed by HbA1c
Change from Baseline in insulin resistance at Week 3.
An oral glucose tolerance test will be performed and glucose, insulin and c-peptide will be measured and combined by the Homeostatic Model Assessment (HOMA) to report insulin resistance.
Change from Baseline in insulin resistance at Week 12.
An oral glucose tolerance test will be performed and glucose, insulin and c-peptide will be measured and combined by the Homeostatic Model Assessment (HOMA) to report insulin resistance.
Change from Baseline in Interleukin-1-B at Week 3.
Change in patients inflammatory status assessed by measurement of Interleukin-1-B.
Change from Baseline in Interleukin-1-B at Week 12.
Change in patients inflammatory status assessed by measurement of Interleukin-1-B.
Change from Baseline in Interleukin-2 at Week 3.
Change in patients inflammatory status assessed by measurement of Interleukin-2.
Change from Baseline in Interleukin-2 at Week 12.
Change in patients inflammatory status assessed by measurement of Interleukin-2.
Change from Baseline in Interleukin-6 at Week 3.
Change in patients inflammatory status assessed by measurement of Interleukin-6.
Change from Baseline in Interleukin-6 at Week 12.
Change in patients inflammatory status assessed by measurement of Interleukin-6.
Change from Baseline in Interleukin-10 at Week 3.
Change in patients inflammatory status assessed by measurement of Interleukin-10.
Change from Baseline in Interleukin-10 at Week 12.
Change in patients inflammatory status assessed by measurement of Interleukin-10.
Change from Baseline in Interferon-a at Week 3.
Change in patients inflammatory status assessed by measurement of Interferon-a.
Change from Baseline in Interferon-a at Week 12.
Change in patients inflammatory status assessed by measurement of Interferon-a.
Change from Baseline in Interferon-B at Week 3.
Change in patients inflammatory status assessed by measurement of Interferon-B.
Change from Baseline in Interferon-B at Week 12.
Change in patients inflammatory status assessed by measurement of Interferon-B.
Change from Baseline in Interferon-y at Week 3.
Change in patients inflammatory status assessed by measurement of Interferon-y.
Change from Baseline in Interferon-y at Week 12.
Change in patients inflammatory status assessed by measurement of Interferon-y.
Change from Baseline in Tumor Necrosis Factor-a at Week 3.
Change in patients inflammatory status assessed by measurement of Tumor Necrosis Factor-a.
Change from Baseline in Tumor Necrosis Factor-a at Week 12.
Change in patients inflammatory status assessed by measurement of Tumor Necrosis Factor-a.
Change from Baseline in High Sensitivity C-Reactive Protein at Week 3.
Change in patients inflammatory status assessed by measurement of High Sensitivity C-Reactive Protein.
Change from Baseline in High Sensitivity C-Reactive Protein at Week 12.
Change in patients inflammatory status assessed by measurement of High Sensitivity C-Reactive Protein.
Full Information
NCT ID
NCT04504045
First Posted
July 29, 2020
Last Updated
June 14, 2022
Sponsor
University of Southern Denmark
1. Study Identification
Unique Protocol Identification Number
NCT04504045
Brief Title
Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
Official Title
INFLAMMATION AND DRUG METABOLISM - Does the Effect of Drugs Decrease When Patients With Type 2 Diabetes Initiate Antidiabetic Treatment?
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Terminated
Why Stopped
Slow recruitment due to COVID-19, the study was stopped when recruited numbers fulfilled the pre-defined lower sample size.
Study Start Date
September 1, 2020 (Actual)
Primary Completion Date
May 10, 2022 (Actual)
Study Completion Date
May 10, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Southern Denmark
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Type 2 diabetes is a major public health concern. It is widely established that type 2 diabetes in linked to activated innate immunity and increased levels of C-reactive protein and interleukin-6 (IL-6) in plasma. Studies in humans and in liver cells has shown that IL-6 downregulates important drug metabolizing enzymes in the liver (cytochrome P450 (CYP) enzymes). More than half of the most prescribed drugs are eliminated by biotransformation of these enzymes.
The investigators have previously shown that initiating glucose-lowering treatment (e.g. metformin, sulphonylureas and insulin) leads to decreased therapeutic efficacy of the blood-thinning vitamin-K antagonist warfarin. Due to the non-specific effect of glucose lowering drugs, the investigators hypothesize that this is caused by the glucose-lowering effect rather than drug-drug interactions caused by the individual drugs.
Based on the proposal that reversal of increased plasma glucose affects drug metabolism, the investigators will perform a clinical pharmacokinetic trial. The purpose of the study is to elucidate whether initiation of glucose-lowering treatment causes altered drug metabolism among patients with type 2 diabetes. The study will include newly diagnosed and untreated type 2 diabetes patients who will ingest a 6-drug cocktail consisting of probes for specific CYP enzymes. Plasma and urine will be drawn over 6 hours to determine concentrations of the drugs and their metabolites. Patients will then initiate metformin treatment and to assess both short- and long-term impact of glucose-lowering, the same 6-drug cocktail will be ingested, and concentrations measured, after three weeks and three months. To help understand the mechanism and the putative involvement of inflammation, markers of inflammation such as cytokines, transcription factors, etc. will also be assesses.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Metformin
Arm Type
Experimental
Arm Description
Patients will receive metformin 1000-2000 mg daily for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucose lowering treatment
Intervention Description
500 mg tablet
Intervention Type
Drug
Intervention Name(s)
Caffeine
Intervention Description
As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
Intervention Type
Drug
Intervention Name(s)
Efavirenz
Intervention Description
As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
Intervention Type
Drug
Intervention Name(s)
Losartan
Intervention Description
As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
Intervention Type
Drug
Intervention Name(s)
Omeprazol
Intervention Description
As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
Intervention Type
Drug
Intervention Name(s)
Metoprolol
Intervention Description
As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
Intervention Type
Drug
Intervention Name(s)
Midazolam
Intervention Description
As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
Primary Outcome Measure Information:
Title
Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 3.
Description
Change in activity of the drug metabolizing enzyme CYP3A4 following treatment with the glucose lowering drug metformin in 3 weeks. Assessment of the change is based on a change in the metabolic rate, which is the ratio between the concentration of midazolam and its primary metabolite is plasma (Probe drug for CYP3A4).
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 12.
Description
Change in activity of the drug metabolizing enzyme CYP3A4 following treatment with the glucose lowering drug metformin in 12 weeks. Assessment of the change is based on a change in the metabolic rate, which is the ratio between the concentration of midazolam and its primary metabolite is plasma (Probe drug for CYP3A4).
Time Frame
Baseline and Week 12.
Secondary Outcome Measure Information:
Title
Change from Baseline in Metabolic Rate of Caffeine (CYP1A2) at Week 3.
Description
Change in activity of the drug metabolizing enzymes CYP1A2 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug caffeine.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Metabolic Rate of Caffeine (CYP1A2) at Week 12.
Description
Change in activity of the drug metabolizing enzymes CYP1A2 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug caffeine.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Metabolic Rate of Efavirenz (CYP2B6) at Week 3.
Description
Change in activity of the drug metabolizing enzymes CYP2B6 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Efavirenz.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Metabolic Rate of Efavirenz (CYP2B6) at Week 12.
Description
Change in activity of the drug metabolizing enzymes CYP2B6 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Efavirenz.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Metabolic Rate of Losartan (CYP2C9) at Week 3.
Description
Change in activity of the drug metabolizing enzymes CYP2C9 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Losartan.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Metabolic Rate of Losartan (CYP2C9) at Week 12.
Description
Change in activity of the drug metabolizing enzymes CYP2C9 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Losartan.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Metabolic Rate of Omeprazole (CYP2C19) at Week 3.
Description
Change in activity of the drug metabolizing enzymes CYP2C19 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Omeprazole.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Metabolic Rate of Omeprazole (CYP2C19) at Week 12.
Description
Change in activity of the drug metabolizing enzymes CYP2C19 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Omeprazole.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Metabolic Rate of Metoprolol (CYP2D6) at Week 3.
Description
Change in activity of the drug metabolizing enzymes CYP2D6 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Metoprolol.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Metabolic Rate of Metoprolol (CYP2D6) at Week 12.
Description
Change in activity of the drug metabolizing enzymes CYP2D6 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Metoprolol.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in HbA1c at Week 3.
Description
Change in the regulation of blood glucose over time assessed by HbA1c
Time Frame
Baseline and Week 3.
Title
Change from Baseline in HbA1c at Week 12.
Description
Change in the regulation of blood glucose over time assessed by HbA1c
Time Frame
Baseline and Week 12.
Title
Change from Baseline in insulin resistance at Week 3.
Description
An oral glucose tolerance test will be performed and glucose, insulin and c-peptide will be measured and combined by the Homeostatic Model Assessment (HOMA) to report insulin resistance.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in insulin resistance at Week 12.
Description
An oral glucose tolerance test will be performed and glucose, insulin and c-peptide will be measured and combined by the Homeostatic Model Assessment (HOMA) to report insulin resistance.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Interleukin-1-B at Week 3.
Description
Change in patients inflammatory status assessed by measurement of Interleukin-1-B.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Interleukin-1-B at Week 12.
Description
Change in patients inflammatory status assessed by measurement of Interleukin-1-B.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Interleukin-2 at Week 3.
Description
Change in patients inflammatory status assessed by measurement of Interleukin-2.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Interleukin-2 at Week 12.
Description
Change in patients inflammatory status assessed by measurement of Interleukin-2.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Interleukin-6 at Week 3.
Description
Change in patients inflammatory status assessed by measurement of Interleukin-6.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Interleukin-6 at Week 12.
Description
Change in patients inflammatory status assessed by measurement of Interleukin-6.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Interleukin-10 at Week 3.
Description
Change in patients inflammatory status assessed by measurement of Interleukin-10.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Interleukin-10 at Week 12.
Description
Change in patients inflammatory status assessed by measurement of Interleukin-10.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Interferon-a at Week 3.
Description
Change in patients inflammatory status assessed by measurement of Interferon-a.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Interferon-a at Week 12.
Description
Change in patients inflammatory status assessed by measurement of Interferon-a.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Interferon-B at Week 3.
Description
Change in patients inflammatory status assessed by measurement of Interferon-B.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Interferon-B at Week 12.
Description
Change in patients inflammatory status assessed by measurement of Interferon-B.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Interferon-y at Week 3.
Description
Change in patients inflammatory status assessed by measurement of Interferon-y.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Interferon-y at Week 12.
Description
Change in patients inflammatory status assessed by measurement of Interferon-y.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in Tumor Necrosis Factor-a at Week 3.
Description
Change in patients inflammatory status assessed by measurement of Tumor Necrosis Factor-a.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in Tumor Necrosis Factor-a at Week 12.
Description
Change in patients inflammatory status assessed by measurement of Tumor Necrosis Factor-a.
Time Frame
Baseline and Week 12.
Title
Change from Baseline in High Sensitivity C-Reactive Protein at Week 3.
Description
Change in patients inflammatory status assessed by measurement of High Sensitivity C-Reactive Protein.
Time Frame
Baseline and Week 3.
Title
Change from Baseline in High Sensitivity C-Reactive Protein at Week 12.
Description
Change in patients inflammatory status assessed by measurement of High Sensitivity C-Reactive Protein.
Time Frame
Baseline and Week 12.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes, not treated metformin.
Hemoglobin 1Ac (HbA1c): ≥48 mmol/mol
Age: 18-75 years
Body Mass Index (BMI) ≤ 40 kg/m2
Estimated Glomerular Filtration Rate (eGFR) > 60 mL/min
Alanine Aminotransferase (ALAT), bilirubin and hemoglobin within reference range or clinically insignificant differ from this.
Exclusion Criteria:
Acute or chronic infection or inflammation
Active cancer
Glutamic acid decarboxylase (GAD)-antibodies
Known hypersensitivity to one or several of the drugs
Intake of medications which can influence the safety of the patient or the results of the study
Alcohol consumption above the limits recommended by the Danish Health Authorities (Men 14 units/week, women 7 units/week)
Participation in other trials with interventions.
Women: Positive pregnancy test at inclusion or on one of the test-days.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ann-Cathrine Dunvald, MD
Organizational Affiliation
University of Southern Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Southern Denmark
City
Odense
State/Province
Region Of Southern Denmark
ZIP/Postal Code
5000
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Individual participant data cannot be shared due to general data protection regulation (GDPR).
Citations:
PubMed Identifier
26559049
Citation
Stage TB, Pottegard A, Henriksen DP, Christensen MM, Hojlund K, Brosen K, Damkier P. Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study. J Thromb Haemost. 2016 Jan;14(1):129-33. doi: 10.1111/jth.13187. Epub 2015 Dec 29.
Results Reference
background
Learn more about this trial
Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs